20/20 OptimEyes Technologies has developed a mucoadhesive drug delivery platform technology that allows for improved solubility of APIs and extended-release. Validated as an eye drop, with successful pre-clinical studies in glaucoma, dry eye and uveitis, the company is seeking partners to further develop these assets or test new indications in human disease applications or companion animals.

Event details

Date: June 3 - 6, 2024

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


42 in total